A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis

2025-522892-27-00 · tracked via the Priya Life Science EU tracker

Sponsor

GSK PLC

Sponsor type

Pharmaceutical company

Therapeutic area

Respiratory Tract Diseases

Decision date

09/02/2026

Enrollment target

207

Sites

Denmark, France, Spain, Italy, Germany, Poland

Condition studied

Bronchiectasis

Investigational medicinal product(s)

5% Dextrose Injection is a solution for injection

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

What is the percentage reduction in annualized exacerbation rate on GSK3862995B versus placebo, in adult patients with bronchiectasis and recurrent exacerbations or uncontrolled symptoms assuming no study treatment discontinuation occurred, change in maintenance SOC or use of prohibited medications.

Endpoint detail

1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522892-27-00 on CTIS ↗ ← All trials in the EU